Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Biotechnologies Raises $6.4M to Support FDA Submission

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today announced the closing of a financing round that raised $6.4 million.

The funding includes $4 million in new capital and the conversion of $2.4 million in outstanding notes into preferred stock, the Pittsfield, Mass.-based firm said.

In August GenomeWeb Daily News reported the company had closed on a Series B round that raised $4.7 million. The $6.4 million reported today includes the earlier amount, a company spokesman said.

The funding will be used to support regulatory approval of its fatty acid synthase assay, including clinical trials, as well as facility upgrades, new hires, and general operations. Nuclea CEO Patrick Muraca said in August that the company planned to submit its fatty acid synthase assay for approval from the US Food and Drug Administration by the end of September.

It is unclear whether the company has yet made its submission.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.